Immune cell therapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 70 years old
- Diagnosed with hepatocellular carcinoma (liver cancer) at BCLC stage B or C
- Expected to live at least 3 more months
- Liver function is Child-Pugh grade A or B (moderately good) and no hepatic encephalopathy (brain issues from liver disease)
- Heart function (LVEF) is 50% or higher
- Good enough daily activity level (ECOG 0 to 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This trial tests a new immune cell therapy (gamma-delta T cells) combined with other drugs for people with liver cancer who have not had treatment before. It may help shrink the tumor or slow its growth.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.